Revance Therapeutics Inc (NAS:RVNC)
$ 2.89 0.09 (3.21%) Market Cap: 301.86 Mil Enterprise Value: 490.12 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 59/100

Revance Therapeutics Inc at Credit Suisse Healthcare Conference (Virtual) Transcript

Nov 10, 2020 / 03:15PM GMT
Release Date Price: $25.74 (-6.76%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Hello everyone, my name is Evan Seigerman. I'm the senior large cap bio pharma analyst here at Credit Suisse. And welcome to day 2 of the virtual healthcare -- Virtual Global Healthcare Conference. We're looking very much forward to seeing everyone in person next year. But with me today for the 10:15 session is Revance Therapeutics. And from Revance, I have Tobin Schilke, CFO.

Did I get your pronunciation correct?

Tobin C. Schilke
Revance Therapeutics, Inc. - CFO & Principal Accounting Officer

You nailed it, Evan.

Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst

© -

Excellent. And then one thing, so participants on the line, if you want to ask a question to Tobin, please just send me an email at [email protected]. I'm sure many of you have my e-mail address, and I can ask on your behalf

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot